Pulmonary Embolism

This channel includes news and new technology innovations for Pulmonary Embolism. This condition occurs when an artery in the lungs is blocked, usually caused by a blood clot.

News | Stroke

September 13, 2022 — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for ...

Home September 13, 2022
Home
News | Heart Failure

April 20, 2022 – The Pulmonary Hypertension Association (PHA) joins more than 80 organizations around the world on ...

Home April 20, 2022
Home
News | Pulmonary Embolism

February 16, 2022 – Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a ...

Home February 16, 2022
Home
News | Pulmonary Embolism

February 14, 2022 — Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Ica ...

Home February 14, 2022
Home
News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
The Viz.AI pulmonary embolism response team (PERT) app that uses AI to detect PE on images before they go into PACS, alerts the PERT team members and provides a mobile platform to message, review images and other patient data. Photo by Dave Fornell
Feature | Artificial Intelligence | By Dave Fornell, DAIC Editor

Artificial intelligence (AI) has found a unique niche to help automate the activation of acute care teams for pulmonary ...

Home December 09, 2021
Home
News | Pulmonary Embolism

August 9, 2021 — Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative ...

Home August 09, 2021
Home
News | Artificial Intelligence

June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced that it has received certification in the United ...

Home June 07, 2021
Home
Videos | Coronavirus (COVID-19)

Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an ...

Home April 01, 2021
Home
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
News | Thrombectomy Devices

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

Home January 08, 2021
Home
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.
Feature | Coronavirus (COVID-19)

December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants ...

Home December 23, 2020
Home
News | Venous Therapies

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
Subscribe Now